Protein Kinase Diversity Library

Protein kinases play a key role in the regulation of almost all cellular processes and are currently attracting significant interest from the pharmaceutical industry as drug targets. Research on kinase inhibitors as drug candidates has made great progress in the last 15 years, both in basic research and in industry. Members of the protein kinase family account for up to 10% of all existing drug targets in humans. The major challenges faced in the development of potential kinase inhibitor drugs are: selectivity, physical properties (solubility, molecular weight) and pharmacological properties (bioavailability).

BOC Sciences can develop a high-quality protein kinase diversity set, a collection of 2,000 potential small molecule inhibitors of protein and lipid kinases obtained from the BOC Sciences HTS compound collection.

Protein Kinase Diversity Library Design

Considering that many existing kinase inhibitor drugs have more similarities, and most of which are designed and optimized based on approved drugs. The structural diversity of existing drugs is not rich enough, and there is an urgent need to increase the structural diversity of compound libraries used for high-throughput screening (HTS) in the initial stage of drug development.

• We have adopted multiple screening methods and techniques compatible with HTS against kinases to generate compound molecules that contain pharmacophores and molecular backbones that are different from those chemically synthesized inhibitor libraries
• BOC Sciences is also committed to exploring and developing kinase inhibitor classes with novel mechanisms of action and specificity, aiming to design kinase inhibitors with the appropriate selectivity to achieve a ideal balance between efficacy and toxicity

Figure 1. Overview of IL-1R-Mediated Signaling to NF-κB and JNK/p38. (Janssens, S.; Beyaert, R. 2003)

Protein Kinase Diversity Library Characteristics

• Our protein kinase diversity library has a huge potential in expanding the structural diversity of HTS libraries
• Optimal similarity (Tanimoto ≥ 0.82) to known protein kinase inhibitors with confirmed high activity (Ki, ≤ 3 uM, residual activity ≤ 50%, etc.)
• A number of known modulators of protein kinases are included
• High diversity over the screening set: mean Tanimoto = 0.34
• Favorable physicochemical parameters and solubility requirements
• No PAINS or toxic substances/unwanted functions: filtered by strict ‘Ro5-like’ physicochemical and most stringent in-house structural filters
• Bioactivity and safety confirmed by preclinical studies and clinical trials
• Structural diversity, medicinal activity, and cellular penetration
• Structural document, IC₅₀, and other chemical and biological data are provided
• All compounds are continually updated
• Compound cherry-picking service is provided

What We Deliver

• Delivered within 2 weeks in any customer-preferred format
• Powders, dry films or DMSO solutions formatted in vials, 96 or 384-well plates
• All compounds have a minimum purity of 90% assessed by ¹H NMR and HPLC
• Analytical data is provided

BOC Sciences provides professional, rapid and high-quality services of Protein Kinase Diversity Library design at competitive prices for global customers. Personalized and customized services of Protein Kinase Diversity Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!